The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Metabolic Effects of Very‐Low‐Calorie Diet, Semaglutide, or Combination of the Two, in Individuals With Type 2 Diabetes Mellitus
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Three trials had some concerns due to either small sample size or unblinded counseling.
“Three trials had some concerns due to either small sample size or unblinded counseling [27, 30, 31].”
From Nutrition Strategies for Next‐Generation Incretin Therapies: A Systematic Scoping Review of the Current Evidence (2026) · cites this paper as [30]
In Anyiam et al. (2024), the combination group achieved greater fat mass loss (9.0 kg vs. 4.0 kg), greater reductions in energy intake (1136 kcal/day vs. 480 kcal/day), and a higher percentage of energy from protein (30.0% vs. 18.6%) than the semaglutide-alone group.
“The combination group achieved greater fat mass loss (9.0 kg compared with 4.0 kg), greater reductions in energy intake (1136 kcal/day compared with 480 kcal/day), and a higher percentage of energy from protein (30.0% compared with 18.6%) than the semaglutide‐alone group.”
From Nutrition Strategies for Next‐Generation Incretin Therapies: A Systematic Scoping Review of the Current Evidence (2026) · cites this paper as [30]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205
Davies, M. J., Aroda, V. R., Collins, B. S., Gabbay, R. A., Green, J., Maruthur, N. M., Rosas, S. E., Del Prato, S., Mathieu, C., Mingrone, G., et al. (2022) · Diabetes Care · doi:10.2337/dci22-0034 · Cited by 2,104
Lean, M. E., Leslie, W. S., Barnes, A. C., Brosnahan, N., Thom, G., McCombie, L., Peters, C., Zhyzhneuskaya, S., Al-Mrabeh, A., Hollingsworth, K. G., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(17)33102-1 · Cited by 2,095
Lim, E. L., Hollingsworth, K. G., Aribisala, B. S., Chen, M. J., Mathers, J. C., & Taylor, R. (2011) · Diabetologia · doi:10.1007/s00125-011-2204-7 · Cited by 1,164
Wadden, T. A., Bailey, T. S., Billings, L. K., Davies, M., Frias, J. P., Koroleva, A., Lingvay, I., O’Neil, P. M., Rubino, D. M., Skovgaard, D., et al. (2021) · JAMA · doi:10.1001/jama.2021.1831 · Cited by 1,114
Taylor, R. (2013) · Diabetes Care · doi:10.2337/dc12-1805 · Cited by 485
Steven, S., Hollingsworth, K. G., Al-Mrabeh, A., Avery, L., Aribisala, B., Caslake, M., & Taylor, R. (2016) · Diabetes Care · doi:10.2337/dc15-1942 · Cited by 418
Sargeant, J. A., Henson, J., King, J. A., Yates, T., Khunti, K., & Davies, M. J. (2019) · Endocrinology and Metabolism · doi:10.3803/enm.2019.34.3.247 · Cited by 231
Vilsbøll, T., Brock, B., Perrild, H., Levin, K., Lervang, H. ‐., Kølendorf, K., Krarup, T., Schmitz, O., Zdravkovic, M., Le‐Thi, T., et al. (2008) · Diabetic Medicine · doi:10.1111/j.1464-5491.2007.02333.x · Cited by 213
Lean, M. E., Leslie, W. S., Barnes, A. C., Brosnahan, N., Thom, G., McCombie, L., Kelly, T., Irvine, K., Peters, C., Zhyzhneuskaya, S., et al. (2024) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(23)00385-6 · Cited by 186
Horn, D. B., Almandoz, J. P., & Look, M. (2022) · Postgraduate Medicine · doi:10.1080/00325481.2022.2051366 · Cited by 114
Hu, S., Su, X., & Fan, G. (2023) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-023-01195-7 · Cited by 28
Kloecker, D. E., Zaccardi, F., Baldry, E., Davies, M. J., Khunti, K., & Webb, D. R. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13727 · Cited by 25
Flagged first, then by citations
Research works printed but not linked: 27
- Abdullah, 2010, The magnitude of association between overweight and obesity and the risk of diabetes: a meta-analysis of prospective cohort studies, Diabetes Res Clin Pract, 89, 309, 10.1016/j.diabres.2010.04.012 · DOI · Paper page
- Esteghamati, 2008, Metabolic syndrome and insulin resistance significantly correlate with body mass index, Arch Med Res, 39, 803, 10.1016/j.arcmed.2008.08.004 · DOI
- Sellahewa, 2017, A systematic review of evidence on the use of very low calorie diets in people with diabetes, Curr Diabetes Rev, 13, 35, 10.2174/1573399812666151005123431 · DOI · Paper page
- DeFronzo, 1992, Pathogenesis of NIDDM: a balanced overview, Diabetes Care, 15, 318, 10.2337/diacare.15.3.318 · DOI · Paper page
- Bower, 2017, The association of percent body fat and lean mass with HbA1c in US adults, J Endocr Soc, 1, 600, 10.1210/js.2017-00046 · DOI
- Zhang, 2015, Associations of different adipose tissue depots with insulin resistance: a systematic review and meta-analysis of observational studies, Sci Rep, 5
- Igarashi, 2023, Effects of changes in body fat mass as a result of regular exercise on hemoglobin A1c in patients with type 2 diabetes mellitus: a meta-analysis, Int J Sport Nutr Exerc Metabol, 33, 209, 10.1123/ijsnem.2022-0217 · DOI
- Sayda, 2022, Caloric restriction improves glycaemic control without reducing plasma branched-chain amino acids or keto-acids in obese men, Sci Rep, 12
- Ardavani, 2021, The effects of very low energy diets and low energy diets with exercise training on skeletal muscle mass: a narrative review, Adv Ther, 38, 149, 10.1007/s12325-020-01562-0 · DOI · Paper page
- Wang, 2024, Glycemic control, weight management, cardiovascular safety, and cost-effectiveness of semaglutide for patients with type 2 diabetes mellitus: a rapid review and meta-analysis of real-world studies, Diabetes Therapy, 15, 497, 10.1007/s13300-023-01520-3 · DOI
- Drucker, 2005, Biologic actions and therapeutic potential of the proglucagon-derived peptides, Nat Clin Pract Endocrinol Metabol, 1, 22, 10.1038/ncpendmet0017 · DOI
- Blundell, 2017, Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity, Diabetes Obes Metabol, 19, 1242, 10.1111/dom.12932 · DOI · Paper page
- Gomez-Peralta, 2019, Profile of semaglutide in the management of type 2 diabetes: design, development, and place in therapy, Drug Des Dev Ther, 13, 731, 10.2147/DDDT.S165372 · DOI
- Kapitza, 2017, Effects of semaglutide on beta cell function and glycaemic control in participants with type 2 diabetes: a randomised, double-blind, placebo-controlled trial, Diabetologia, 60, 1390, 10.1007/s00125-017-4289-0 · DOI
- Uchiyama, 2023, Oral semaglutide induces loss of body fat mass without affecting muscle mass in patients with type 2 diabetes, J Clin Med Res, 15, 377, 10.14740/jocmr4987 · DOI
- 2013, World Medical Association declaration of Helsinki: Ethical principles for medical research involving human subjects, JAMA, 310, 2191, 10.1001/jama.2013.281053 · DOI · Paper page
- Bingley, 1992, Standardization of IVGTT to predict IDDM, Diabetes Care, 15, 1313, 10.2337/diacare.15.10.1313 · DOI
- Hannon, 2018, Review of methods for measuring β-cell function: design considerations from the restoring insulin secretion (RISE) consortium, Diabetes Obes Metab, 20, 14, 10.1111/dom.13005 · DOI
- Cersosimo, 2014, Assessment of pancreatic β-cell function: review of methods and clinical applications, Curr Diabetes Rev, 10, 2, 10.2174/1573399810666140214093600 · DOI
- Liu, 2015, Effects of a very low-calorie diet on insulin sensitivity and insulin secretion in overweight/obese and lean type 2 diabetes patients, Diabetes Metab, 41, 513, 10.1016/j.diabet.2015.09.003 · DOI
- Jackness, 2013, Very low-calorie diet mimics the early beneficial effect of Roux-en-Y gastric bypass on insulin sensitivity and β-cell Function in type 2 diabetic patients, Diabetes, 62, 3027, 10.2337/db12-1762 · DOI
- Brown, 2020, Low-energy total diet replacement intervention in patients with type 2 diabetes mellitus and obesity treated with insulin: a randomized trial, BMJ Open Diabetes Res Care, 8, 10.1136/bmjdrc-2019-001012 · DOI
- Anholm, 2017, Liraglutide effects on beta-cell, insulin sensitivity and glucose effectiveness in patients with stable coronary artery disease and newly diagnosed type 2 diabetes, Diabetes Obes Metabol, 19, 850, 10.1111/dom.12891 · DOI
- Silvestre, 2018, The role of glucagon in weight loss-mediated metabolic improvement: a systematic review and meta-analysis, Obes Rev, 19, 233, 10.1111/obr.12631 · DOI
- Jinnouchi, 2015, Liraglutide, a glucagon-like peptide-1 analog, increased insulin sensitivity assessed by hyperinsulinemic-euglycemic clamp examination in patients with uncontrolled type 2 diabetes mellitus, J Diabetes Res, 10.1155/2015/706416 · DOI
- Plum, 2011, Comparison of glucostatic parameters after hypocaloric diet or bariatric surgery and equivalent weight loss, Obesity (Silver Spring), 19, 2149, 10.1038/oby.2011.134 · DOI
- Rubino, 2021, Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial, JAMA, 325, 1414, 10.1001/jama.2021.3224 · DOI · Paper page
Cited by
Sorted by citations
Langer, H. T., Gilmore, N. K., Hayden, C. M. T., Roux, J., Bariohay, B., Rouquet, T., Awada, M., Marcotorchino, J., Bournot, L., Nunn, E., et al. (2026) · Cell Reports Medicine · doi:10.1016/j.xcrm.2026.102665 · Cited by 21
Self-citation
Metadata
- Authors
- Anyiam, O., Phillips, B., Quinn, K., Wilkinson, D., Smith, K., Atherton, P., & Idris, I.
- Venue
- Clinical Nutrition
- Publisher
- Elsevier BV
- Published
- 2024-08
- Volume
- 43
- Issue
- 8
- Pages
- 1907-1913
- ISSN
- 0261-5614
- Cited by
- 40
- References
- 13
- Language
- en
- Licence
- Funders
- Medical Research Council
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
